Pharmaceutical Technology

Swiss drugmaker Novartis has agreed to a licensing deal worth up to $7.8 billion with China's Abogen Biosciences to develop mRNA-based therapies. The agreement gives Novartis access to Abogen's mRNA technology, highlighting growing Western pharmaceutical interest in Chinese biotech assets and keeping momentum behind mRNA platforms beyond vaccines.

Pharmaceutical Technology has published a magazine edition titled 'Keep it cool'. No further details about its contents are available, and there is no indication yet of what specific topic, product or debate the edition addresses beyond the cooling theme suggested by its title.

Swiss drugmaker Novartis has agreed a deal worth about $7.8 billion with China's Abogen Biosciences, according to Reuters. The agreement centres on mRNA technology, marking a significant move by Novartis into the field and a landmark licensing arrangement for a Chinese biotech firm with a major Western pharmaceutical partner.

Waters Corporation (WAT), the US laboratory instrument and analytical technology maker, is seeing its stock price, quote and trading history tracked by investors. The company, listed on the New York Stock Exchange, is a key supplier to the pharmaceutical and industrial testing sectors, making its share performance a regular focus for market watchers and finance news readers.

The AAPS PharmSci 360 conference is presenting new research and perspectives for scientists working across the pharmaceutical industry. Coverage highlights fresh insights on drug discovery and development shared at the event, which gathers industry professionals to discuss scientific advances, regulatory topics, and emerging technologies shaping the pharma field.